For the past decade Roche has brought together the lung cancer community to share expertise, knowledge and solutions to the ever changing treatment landscape of lung cancer. This year, in addition to the 11th annual LCEF, we will also be taking the Lung Cancer Expert Forum digital. Please join us for the second in a series of three virtual meetings, in which we will explore various aspects of lung cancer treatment, sharing expertise from across the country.
A virtual meeting uses live, online interactive technology to allow delegates to access a meeting remotely. You can join the online presentations and ask text-based questions to be answered in the Q&A session at the end of each meeting.
This is an innovative way to learn about recent developments in treatments of lung cancer and to support best practice learning across the community.
All virtual meetings will run from 6.30pm – 7.30pm
Completed: Tuesday 30 July 2019 | Session 1
Fast Progressing NSCLC patients and immunotherapy – what to do? – Dr Tim Benepal
In this session, Dr. Tim Benepal, Consultant Medical Oncologist at St. George’s Hospital, will discuss the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy.
The two year stopping rule, how to handle this conversation with patients and your team – Dr Brian Clark
In this session Dr. Brian Clark, Consultant Clincal Oncologist at the Beatson West of Scotland Cancer Centre, discusses his experiences of effectively communicating with patients, families and the wider MDT. Focusing on delivering bad news, patient consent, and the 2 year immunotherapy stopping rule. He will address questions such as:
- ‘What needs to be included in these conversations?’
- ‘How can you make sure that patients understand the two year stopping rule?’
Wednesday 23 October 2019 | Session 2
18:30 – 18:35: Introduction
18:35 – 18:55: The science of immunotherapy combinations in 1L NSCLC – Professor Gary Middleton, Professor of Medical Oncology at the University of Birmingham.
In this session Professor Gary Middleton, Consultant Medical Oncologist at the Queen Elizabeth Hospital Birmingham will detail the proposed science behind the immunotherapy combinations currently available in the treatment of 1L NSCLC patients. Prof Middleton will specifically discuss and answer questions on Keynote-189 (pembrolizumab, cisplatin and pemetrexed) and IMpower150 (atezolizumab, bevacizumab, carboplatin and paclitaxel) combination therapies.
18:55 – 19:15: Patient Identification, clinical evidence and the practicalities of combination therapy for key patient subgroups in 1L metestatic non-squamous NSCLC – Dr Carles Escriu, Consultant Medical Oncologist at Clatterbridge Cancer Centre.
In this session Dr. Carles Escriu, Consultant Medical Oncologist at the Clatterbridge Cancer Centre will be explaining and sharing his experience on patient identification, clinical evidence and the practicalities of treating 1L metastatic non-squamous NSCLC patients using the IMpower150 regimen (atezolizumab, bevacizumab, carboplatin and paclitaxel).
19:15 – 19:30: Q&A Session
Proposed date: Monday 16 December 2019 | Session 3
Details of speakers and topics will be released shortly
Here are some of the speakers who will be attending the Virtual Lung Cancer Expert Forums:
Gary Middleton is Professor of Medical Oncology at the University of Birmingham. He is the Chief Investigator for a multitude of studies and is also Director of the Cancer Research UK Birmingham Centre. He sits on the NCRI advanced lung sub-group, the NCRI advanced CRC sub- group, EMERP and CRC. His main translational interest is in tumour immunobiology particularly in colorectal and pancreatic cancer.
Dr Carles Escriu completed medical school in Barcelona. He spent several years working as a junior doctor in several UK hospitals including Leeds General Infirmary and Southampton General Hospital before starting oncology training at Oxford’s Churchill Hospital. Dr Escriu completed a cancer biology PhD at the University of Cambridge before obtaining a higher specialist registration in Liverpool. Now a Consultant Medical oncologist at the Clatterbridge cancer centre, Dr Escriu is currently sub-specialised in thoracic oncology with a specialist interest in targeted treatments and immune therapy.
RXUKATEZ00507c October 2019
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing firstname.lastname@example.org or calling +44(0)1707 367554.
As Tecentriq is a biological medicine, Healthcare professionals should report adverse reactions
by brand name and batch number.
This is a promotional meeting organised and funded by Roche Products Ltd.